Erlotinib Completed Phase 2 Trials for Malignant Peritoneal Mesothelioma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01592383Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma